GAMP 5 vs CSA
Two ways to assure computerized systems — and how they now converge.
What a comparison is not
A comparison is SPEQ’s reading of how two published documents differ. Neither is the right answer, it is not a determination of which applies to you, and neither is summarised in a way that replaces reading it.
GAMP 5 is ISPE’s risk-based framework for validating computerized systems across the pharmaceutical lifecycle. CSA — Computer Software Assurance — is the FDA’s least-burdensome, critical-thinking approach for software used in medical-device production and quality systems. They are often framed as rivals, but the GAMP 5 second edition explicitly embraced the same critical-thinking mindset, so the real question is scope, not conflict.
| ASPECT | GAMP 5 | CSA |
|---|---|---|
| Who publishes it | ISPE (industry body); adopted globally | FDA (CDRH); a US guidance document |
| Primary scope | Any GxP computerized system across the pharma lifecycle | Software for medical-device production and the quality system |
| Core idea | Scale validation effort to risk and to the software category (1/3/4/5) | Lead with intended use + risk, then choose the least-burdensome assurance activity |
| Testing emphasis | Documented, often scripted testing sized to risk | Unscripted / ad-hoc and exploratory testing encouraged where risk is low |
| Leveraging the vendor | Supplier assessment can reduce testing (esp. Category 3/4) | Explicitly leans on vendor activities to avoid duplicative testing |
| Documentation posture | Right-sized documentation; avoid “validation for its own sake” | Record the assurance rationale; minimise evidence that adds no assurance |
| Relationship | GAMP 5 (2nd ed.) absorbed CSA’s critical-thinking concepts | CSA operationalises the mindset GAMP 5 now shares |
Reach for GAMP 5 as the everyday framework for pharmaceutical computerized-system validation — LIMS, MES, ERP, historians — where you need a category-based, lifecycle approach regulators worldwide recognise.
Apply CSA when the software supports medical-device production or the device quality system, and you want FDA’s explicit blessing to replace scripted-test volume with critical thinking, unscripted testing, and vendor leverage.
They are not opposites. GAMP 5 is the framework; CSA is a mindset (and an FDA guidance) for spending validation effort where it actually buys assurance. Modern practice runs GAMP 5’s risk-based lifecycle with CSA’s critical-thinking lens — most of the argument disappears once you separate scope (device vs all-GxP) from philosophy (both now agree: assurance, not paperwork).
GAMP 5 vs CSA: frequently asked questions
Common questions on how GAMP 5 and CSA differ and when each applies.
Does CSA replace GAMP 5?
No. CSA is an FDA guidance scoped to medical-device production and quality-system software; GAMP 5 is an industry framework covering all GxP computerized systems. The GAMP 5 second edition already incorporates CSA’s critical-thinking approach, so they are used together, not swapped.
Is CSA only for medical devices?
The FDA’s CSA final guidance is scoped to software used in device production and the quality system. Its principles (risk-first, least-burdensome, critical thinking) are widely borrowed elsewhere, but do not assume the FDA applies CSA to pharma manufacturing, clinical, or pharmacovigilance software.
Does CSA mean less documentation?
It means less low-value documentation. CSA asks you to record the assurance rationale and the testing that actually reduces risk — and to stop producing evidence that adds no assurance. It is a reallocation of effort, not an exemption.
Which one satisfies 21 CFR Part 11?
Neither is a Part 11 substitute. Part 11 governs electronic records and signatures; GAMP 5 and CSA are approaches to assuring the system that produces them. You still meet Part 11 controls (audit trails, access, e-signatures) regardless of which assurance approach you use.